Cerity Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $127M | Sell |
255,874
-40,780
| -14% | -$18.1M | 0.15% | 132 |
|
|
2026
Q1 | $132M | Buy |
296,654
+35,101
| +13% | +$16.4M | 0.19% | 112 |
|
|
2025
Q4 | $119M | Buy |
261,553
+2,745
| +1% | +$1.18M | 0.17% | 118 |
|
|
2025
Q3 | $101M | Sell |
258,808
-4,884
| -2% | -$2.04M | 0.16% | 125 |
|
|
2025
Q2 | $117M | Buy |
263,692
+10,768
| +4% | +$4.96M | 0.21% | 100 |
|
|
2025
Q1 | $123M | Buy |
252,924
+14,895
| +6% | +$6.94M | 0.25% | 87 |
|
|
2024
Q4 | $97.5M | Buy |
238,029
+8,987
| +4% | +$4.17M | 0.21% | 98 |
|
|
2024
Q3 | $107M | Buy |
229,042
+29,225
| +15% | +$14M | 0.24% | 90 |
|
|
2024
Q2 | $93.7M | Buy |
199,817
+5,085
| +3% | +$2.21M | 0.25% | 83 |
|
|
2024
Q1 | $81.4M | Buy |
194,732
+63,837
| +49% | +$27M | 0.22% | 102 |
|
|
2023
Q4 | $53.3M | Buy |
130,895
+58,974
| +82% | +$21.8M | 0.18% | 130 |
|
|
2023
Q3 | $25M | Buy |
71,921
+23,232
| +48% | +$8.13M | 0.12% | 166 |
|
|
2023
Q2 | $17.1M | Buy |
48,689
+8,958
| +23% | +$3.02M | 0.07% | 255 |
|
|
2023
Q1 | $16.3M | Buy |
39,731
+35,687
| +882% | +$10.7M | 0.04% | 275 |
|
|
2022
Q4 | $1.17M | Buy |
4,044
+1,267
| +46% | +$386K | 0.01% | 654 |
|
|
2022
Q3 | $804K | Buy |
2,777
+223
| +9% | +$64.2K | 0.01% | 565 |
|
|
2022
Q2 | $720K | Buy |
2,554
+724
| +40% | +$194K | 0.01% | 634 |
|
|
2022
Q1 | $478K | Sell |
1,830
-504
| -22% | -$120K | 0.01% | 604 |
|
|
2021
Q4 | $515K | Buy |
2,334
+821
| +54% | +$160K | 0.01% | 587 |
|
|
2021
Q3 | $274K | Buy |
1,513
+43
| +3% | +$8.4K | 0.01% | 585 |
|
|
2021
Q2 | $296K | Buy |
1,470
+107
| +8% | +$22.4K | 0.01% | 583 |
|
|
2021
Q1 | $293K | Buy |
1,363
+82
| +6% | +$18K | 0.01% | 561 |
|
|
2020
Q4 | $303K | Buy |
1,281
+193
| +18% | +$44.3K | 0.01% | 516 |
|
|
2020
Q3 | $296K | Sell |
1,088
-88
| -7% | -$24.3K | 0.01% | 410 |
|
|
2020
Q2 | $341K | Buy |
1,176
+14
| +1% | +$3.8K | 0.02% | 333 |
|
|
2020
Q1 | $276K | Buy |
1,162
+100
| +9% | +$22.9K | 0.02% | 356 |
|
|
2019
Q4 | $233K | Sell |
1,062
-651
| -38% | -$132K | 0.01% | 474 |
|
|
2019
Q3 | $290K | Buy |
1,713
+105
| +7% | +$18.6K | 0.02% | 401 |
|
|
2019
Q2 | $295K | Sell |
1,608
-326
| -17% | -$57K | 0.02% | 402 |
|
|
2019
Q1 | $356K | Sell |
1,934
-438
| -18% | -$80.9K | 0.02% | 383 |
|
|
2018
Q4 | $393K | Sell |
2,372
-138
| -5% | -$23.9K | 0.03% | 356 |
|
|
2018
Q3 | $484K | Buy |
2,510
+1,028
| +69% | +$183K | 0.03% | 338 |
|
|
2018
Q2 | $252K | Buy |
+1,482
| New | +$230K | 0.02% | 461 |
|
Other funds holding VRTX
VCM
VPM
Cerity Partners's VRTX Position: Q2 2026 in Review
Cerity Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 14% in Q2 2026, selling an estimated $18.1M and leaving 255,874 shares worth $127M. The position accounts for 0.15% of the portfolio, ranked #132.
Cerity Partners first reported a position in VRTX in Q2 2018 and has held it in 33 quarters since. The position peaked at $132M in Q1 2026. 1,572 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Cerity Partners held 255,874 shares of Vertex Pharmaceuticals worth $127M as of Q2 2026.
- Cerity Partners sold 40,780 Vertex Pharmaceuticals shares in Q2 2026, an estimated $18.1M.
- Vertex Pharmaceuticals made up 0.15% of Cerity Partners's portfolio in Q2 2026, its #132 holding.
- Cerity Partners first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- Cerity Partners's Vertex Pharmaceuticals position peaked at $132M in Q1 2026.
- 1,572 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.